AUS
NZ
UK
CA
USA
IND
Highlights
ASX 200 Health Care sector underperforms broader index despite isolated stock rallies
Amplia Therapeutics records complete cancer responses in ACCENT trial
Neuro and radiopharma companies advance on clinical updates and acquisitions
The ASX 200 Health Care Index recorded a mild decline in June, marking another challenging month for the sector amid global policy shifts and local end-of-financial-year trading. Despite the broader index showing resilience, the healthcare segment continued to face sector-specific pressures, particularly around regulatory changes and tax loss-related selling activity.
Some ASX-listed biotech stocks, however, delivered sharp upward momentum on the back of promising clinical announcements and strategic developments.
Amplia Surges on Encouraging Cancer Trial Outcomes
Amplia Therapeutics (ASX:ATX) was among the strongest performers in June, driven by positive outcomes from its ACCENT trial in metastatic pancreatic cancer. The company’s lead FAK inhibitor, narmafotinib, when used with standard chemotherapies, achieved complete pathological responses in two patients — a development welcomed in the rare and aggressive cancer space.
The month also saw Amplia receive regulatory approval in the US to initiate a new Phase II study using narmafotinib with FOLFIRINOX, another frontline treatment for advanced pancreatic cancer.
NeuroScientific Jumps Following Stem Cell Technology Acquisition
NeuroScientific Biopharmaceuticals (ASX:NSB) experienced a notable rise after announcing the acquisition of Isopogen WA, a company that holds rights to the StemSmart stem cell platform. Previous compassionate-use data demonstrated favourable responses in adults and children with steroid-refractory graft-versus-host disease (GvHD).
The proprietary technology is being explored for broader therapeutic use in transplant-related immune complications, contributing to a growing interest in NeuroScientific's pipeline.
Clarity Pharmaceuticals Advances on Trial Data
Clinical-stage radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) saw gains supported by positive topline data from its DISCO and SABRE trials. Cu-SARTATE, the company’s lead diagnostic asset, showed strong performance in imaging neuroendocrine tumours, while Cu-SAR-Bombesin demonstrated efficacy in prostate cancer patients with previously inconclusive scans.
The company's ongoing focus on targeted radio-diagnostic and radiotherapeutic agents has continued to place it in the spotlight among ASX healthcare names.
Neurizon Highlights Progress in Huntington’s Research
Neurizon Therapeutics (ASX:NUZ) reported further validation of its NUZ-001 compound, with new preclinical results in zebrafish and rodents supporting its efficacy in Huntington’s disease models. The data suggested the compound crosses the blood-brain barrier effectively, a critical attribute for treating neurodegenerative diseases.
The update was followed by interest in the company’s future milestones, particularly as the neurotherapeutic pipeline develops toward clinical readiness.
Sector Headwinds Remain Despite Stock-Specific Gains
While names like Amplia, NeuroScientific, Clarity, and Neurizon outperformed, broader pressure on the healthcare index remained evident. Sector analysts cited US policy uncertainty, including drug pricing reforms, as a key driver of cautious sentiment. The timing around the close of the Australian financial year also likely contributed to tax-driven repositioning across portfolios.
